Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method and detection kit to judge whether solid tumors are suited for immunotherapy

A detection kit and immunotherapy technology, which are applied in the determination/inspection of microorganisms, biochemical equipment and methods, measurement devices, etc., can solve the problems of immune system identification and tumor-killing ability evaluation, and achieve an objective response rate improvement and broad The effect of the application foreground

Active Publication Date: 2018-10-09
LEPU MEDICAL TECH (BEIJING) CO LTD
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The biomarkers discovered so far are all focused on local events, and have not evaluated the ability of the immune system to recognize and kill tumors globally

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method and detection kit to judge whether solid tumors are suited for immunotherapy
  • Method and detection kit to judge whether solid tumors are suited for immunotherapy
  • Method and detection kit to judge whether solid tumors are suited for immunotherapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] Example 1 Detection of mutation load

[0072] From April 2016 to November 2017, FFPE (formaldehyde-fixed paraffin-embedded) samples and peripheral blood of tumor tissues from 80 patients with solid tumors were collected. The peripheral blood cfDNA (circulating free DNA) and peripheral blood genomic DNA of these 80 patients with solid tumors were extracted, and the sequencing library was constructed, hybridized and captured, and sequenced on a computer, and bioinformatics analysis was performed on the obtained sequencing data. The process can be found in figure 1 . The tumor mutation burden of peripheral blood CtDNA was calculated according to the following formula 4.

[0073] Mutation load = total number of variations in the sample assay region / size of the target region (Formula 4)

Embodiment 2

[0074] Example 2 Detection of HLA heterozygous deletion

[0075] The tumor tissue and paired peripheral blood genomic DNA of 80 solid tumor patients described in Example 1 were extracted, and seven polymorphic STR sites located in the genomic region where the HLA gene was located were selected, and the seven STRs were detected by fluorescent PCR-capillary electrophoresis The homozygous status of the loci (7 loci are D6S2852, D6S2872, D6S248, D6S1022, D6S265, D6S273, D6S1666), and the heterozygous deletion ratio of each locus is calculated according to the following formula 5. In formula 5, allele 1 is the allele with lower peak height. If the heterozygous deletion ratio is higher than 0.4, it is considered that the heterozygous deletion occurs at this site. Compared with the peripheral blood genomic DNA, if there is a heterozygous deletion at one site, then The HLA status of this sample is heterozygous deletion.

[0076] Heterozygous deletion ratio=1-Ht value=1-[peak height o...

Embodiment 3

[0079] Example 3 Calculate the mRNA expression scores of 18 genes related to T cell inflammation

[0080] RNA was extracted from the tumor tissues of 80 patients with solid tumors in Example 1, and 18 genes related to T cell inflammation (see Table 1) were selected, reverse-transcribed into cDNA, and a fixed amount of external standard was added to the cDNA sample.

[0081] The Ct value of 18 genes related to T cell inflammation, 1 internal reference gene β-actin, and 1 external standard was detected by Q-RT-PCR method (based on taqman probe), and the expression score of each gene was calculated. Then calculate the average value, which is the mRNA expression score of the 18 T cell inflammation-related genes. The calculation method is described below taking the CXCR6 gene as an example: Absolute expression level of CXCR6=absolute copy number of external standard product*2 -ΔΔCt , while ΔΔCt=[Ct(CXCR6)-Ct(internal reference gene)]-[Ct(external standard)-Ct(reference gene)], the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a detection kit to judge whether solid tumors are suited for immunotherapy. The detection kit includes detection reagents for detecting the indexes: tumor mutation load of peripheral blood circulating tumor DNA, HLA typing, HLA state of loss of heterozygosity, PD-L1 membrane expression positive tumor cell percentage, infiltration level of CD8+ immune cells, infiltration level of FOXP3+ immune cells, mRNA expression score of T-cell inflammation related genes, percentage of CD14+CD16-HLA-DR+ monocytes in peripheral blood mononuclear cells, and micro-satellite instability.The invention also provides, correspondingly, a method to judge whether solid tumors are suited for immunotherapy. The kit and method herein can be used to screen patients with solid tumors so as to provide significantly increased objective response rate and have a promising application prospect in terms of clinical screening of patients with solid tumors suited for immunotherapy.

Description

technical field [0001] The invention relates to a method for judging whether a solid tumor is suitable for immunotherapy, especially a method for judging whether a solid tumor is suitable for immunotherapy by using multi-index joint detection and a logistic regression model. The invention also relates to detection kits that can be used in this method. Background technique [0002] Tumor immunotherapy is the most exciting development in cancer treatment in recent years, especially PD-1 / PD-L1 immunotherapy has become a hot topic today. Although PD-1 / PD-L1 blockers have achieved good curative effect and high tolerance in clinical practice, there will be significant individual differences in the clinical application of immune checkpoint drugs, and different patients will not respond to the same drug. different drug sensitivities. Except in advanced Hodgkin's lymphoma, the objective response rate of PD-1 blockade was 60%. In tumors, the objective response rate did not exceed 3...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/02C12Q1/6886
CPCG01N33/5005C12Q1/6886C12Q2600/106C12Q2600/158
Inventor 韩玉卿徐芹李俊辉张江生王凯琳蒲珏
Owner LEPU MEDICAL TECH (BEIJING) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com